These are the stocks posting the largest moves before the bell.Market Insiderread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
U.S. stock index futures jumped Wednesday morning after Treasury Secretary Steven Mnuchin told CNBC that the U.S. and China were close to reaching a trade deal.US Marketsread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and its hurting America," he told Yahoo Finance Tuesday.Economyread more
Trump is willing to talk with Iran, but he's "also determined to enforce the U.S. and our allies' interests in the region," Mnuchin tells CNBC.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Mortgage application volume was 40% higher than a year ago, largely because lower rates are strengthening the refinance market.Real Estateread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.Biotech and Pharmaceuticalsread more
Omada Health just raised $73 million at a valuation of around $600 million as it seeks to expand its digital health offerings.Technologyread more
U.S. President Donald Trump and Chinese President Xi Jinping may have put their tit-for-tat tariff fight on hold, but differences between the two countries' views on technology and state-supported businesses will challenge negotiations between the two economic giants, analysts said.
"Staunchly committed to the Chinese economic model, Xi will continue to lend state support to targeted industries, particularly in technology under the Made in China 2025 programme, " Eleanor Olcott, China policy analyst at research firm TS Lombard, wrote on Monday.
Washington has accused China of forcing technology transfers, and tacitly supporting intellectual property violations and cyber-crime, but those issues were downplayed in official descriptions of the weekend's agreement.
"Despite White House economic advisor (Larry) Kudlow suggesting that the two sides are 'pretty close' on an agreement on intellectual property theft, 90 days still looks like a short period for discussions on complicated issues such as non-tariff barriers," wrote Zhu Huani, an economist at Mizuho Bank in a note on Tuesday.
"Whilst reducing (the) trade gap could be the easier part to begin with, China is less likely to make concessions on its industrial policies such as 'Made in China 2025,' which might hinder discussion surrounding technology transfer," added Zhu.
The "Made in China 2025" plan is Beijing's industrial policy to invest heavily in high-end technologies such as artificial intelligence in a bid to catch up with rivals like the U.S. and Germany.
The analysts' comments follow Trump and Xi's agreement over the weekend at the G-20 meeting in Argentina to put their bilateral trade war on pause momentarily. They would, according to official statements, hold off on slapping additional tariffs on each other's goods after Jan. 1 as talks continue between both countries.
As part of the deal, China said it would purchase more American imports, particularly in energy and agriculture. Beijing will also exert more control over the flow of fentanyl — a synthetic opioid that is 50 times more addictive than heroin and has been linked to thousands of overdose deaths in the United States. China is one of the world's top producers of ingredients used to manufacture fentanyl, according to the U.S. Department of Justice.
But, "it is unclear how this [deal at the G-20] will resolve issues related to IP protection and forced technology transfers in China — it won't," economists from French trade credit insurer Coface wrote in a note on Monday.
After all, some are even jokingly questioning if Trump and Xi even attended the same meeting given the significant differences in statements from the two sides.
"There is reason to believe the two parties do not quite meet over the finer details of the deal: pointedly, no joint statement was released after the meeting. Furthermore, the statements that the U.S. and China issued separately showed material divergences, with the Chinese statement making no mention of the 90-day deadline on the threatened 25 percent tariff increase," economists from Pictet Wealth Management wrote Monday.
Neither side referred to the "Made in China 2025" industrial policy, Pictet noted.
"Given the differences in starting positions, with the Chinese side setting red lines around its state-led system, it is highly unlikely that the time-frame of 90 days will allow the U.S. to extract concessions Trump could present as a large-scale 'win' with any degree of conviction," said TS Lombard's Olcott.
—CNBC's Kevin Breuninger, Javier David and Saheli Roy Choudhury contributed to this report.
Disclosure: Larry Kudlow is a former CNBC contributor.